Oncolytics Biotech Stock Performance
| ONC Stock | CAD 1.32 0.06 4.35% |
Oncolytics Biotech has a performance score of 2 on a scale of 0 to 100. The company holds a Beta of -1.01, which implies a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Oncolytics Biotech are expected to decrease slowly. On the other hand, during market turmoil, Oncolytics Biotech is expected to outperform it slightly. Oncolytics Biotech right now holds a risk of 5.35%. Please check Oncolytics Biotech maximum drawdown, skewness, and the relationship between the total risk alpha and downside variance , to decide if Oncolytics Biotech will be following its historical price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Oncolytics Biotech are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating fundamental indicators, Oncolytics Biotech may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
Last Split Factor 105:1000 | Dividend Date 2018-05-25 | Last Split Date 2018-05-25 |
1 | Investors Watch Key Players in Oncology as Cancer Cases Set to Skyrocket - Baystreet.ca | 09/20/2024 |
2 | Stocks In Play Oncolytics Biotech Inc - Barchart | 11/11/2024 |
| Begin Period Cash Flow | 11.7 M |
Oncolytics |
Oncolytics Biotech Relative Risk vs. Return Landscape
If you would invest 128.00 in Oncolytics Biotech on September 3, 2024 and sell it today you would earn a total of 4.00 from holding Oncolytics Biotech or generate 3.13% return on investment over 90 days. Oncolytics Biotech is generating 0.1773% of daily returns assuming 5.3475% volatility of returns over the 90 days investment horizon. Simply put, 47% of all stocks have less volatile historical return distribution than Oncolytics Biotech, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Oncolytics Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncolytics Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oncolytics Biotech, and traders can use it to determine the average amount a Oncolytics Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0332
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ONC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.35 actual daily | 47 53% of assets are more volatile |
Expected Return
| 0.18 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Oncolytics Biotech is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncolytics Biotech by adding it to a well-diversified portfolio.
Oncolytics Biotech Fundamentals Growth
Oncolytics Stock prices reflect investors' perceptions of the future prospects and financial health of Oncolytics Biotech, and Oncolytics Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncolytics Stock performance.
| Return On Equity | -1.38 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | 83.2 M | ||||
| Shares Outstanding | 77.07 M | ||||
| Price To Earning | (4.18) X | ||||
| Price To Book | 11.23 X | ||||
| EBITDA | (33.71 M) | ||||
| Net Income | (27.75 M) | ||||
| Cash And Equivalents | 11.67 M | ||||
| Cash Per Share | 0.72 X | ||||
| Total Debt | 423 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.81 X | ||||
| Book Value Per Share | 0.37 X | ||||
| Cash Flow From Operations | (28.45 M) | ||||
| Earnings Per Share | (0.36) X | ||||
| Market Capitalization | 106.36 M | ||||
| Total Asset | 38.82 M | ||||
| Retained Earnings | (446 M) | ||||
| Working Capital | 33.94 M | ||||
| Current Asset | 26.92 M | ||||
| Current Liabilities | 2.71 M | ||||
About Oncolytics Biotech Performance
By examining Oncolytics Biotech's fundamental ratios, stakeholders can obtain critical insights into Oncolytics Biotech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Oncolytics Biotech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.71) | (0.75) | |
| Return On Capital Employed | (0.98) | (1.03) | |
| Return On Assets | (0.71) | (0.75) | |
| Return On Equity | (1.01) | (0.96) |
Things to note about Oncolytics Biotech performance evaluation
Checking the ongoing alerts about Oncolytics Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oncolytics Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncolytics Biotech had very high historical volatility over the last 90 days | |
| Oncolytics Biotech may become a speculative penny stock | |
| Net Loss for the year was (27.75 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oncolytics Biotech has accumulated about 11.67 M in cash with (28.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.72. | |
| Latest headline from news.google.com: Stocks In Play Oncolytics Biotech Inc - Barchart |
- Analyzing Oncolytics Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncolytics Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Oncolytics Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncolytics Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncolytics Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oncolytics Biotech's stock. These opinions can provide insight into Oncolytics Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.